Seller record · Telehealth service

VivioMD

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 1 of 8 criteria. S5, analytical documentation: No certificate of analysis or lot document is published on the home page, the product page, the terms or the refund policy.

At a glance

VivioMDTelehealth service

7/8criteria passed

Price: Compounded semaglutide injection $249 a month; GLP-1 tablets $279 a month
Sells: compounded semaglutide injection, GLP-1+GIP injection, GLP-1 tablets, and 1 more
FDA letters: 1 on file

Visit VivioMD See all eight dispositions

Telehealth service. Passes 7 of 8 criteria. Recorded against Standard v1.1.

A telehealth weight loss service that connects patients with an outside medical group after an online assessment and sells compounded GLP-1 and GLP-1/GIP injections and dissolving tablets at flat monthly prices, filled by three named pharmacies.

Operating entity VivioMD Group LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	VivioMD's website; VivioMD's terms of use page
S2	Prescription gating	PASS	VivioMD's website
S3	Pharmacy identification	PASS	VivioMD's terms of use page
S4	Compounding disclosure	PASS	VivioMD's website
S5	Analytical documentation	FAIL	VivioMD's website; VivioMD's terms of use page; VivioMD's refund policy
S6	Business address	PASS	VivioMD's terms of use page
S7	Price disclosure	PASS	VivioMD's website
S8	Enforcement status	PASS	FDA's website; FDA warning letter 728295

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSClinicians from OpenLoop Healthcare Partners P.C. and its affiliated professional entities review each online evaluation and determine eligibility before any prescription is sent to a pharmacy.Source: VivioMD's website; VivioMD's terms of use page.

S2PASSThe steps list a five-minute medical assessment first, then a provider consultation, then delivery, and the home page promises a full refund to anyone who is not approved.Source: VivioMD's website.

S3PASSThe terms name the pharmacies that fill prescriptions, with street addresses: RedRock Pharmacy in St. George, Utah and Triad Rx in Daphne, Alabama for compounded medications, and Health Warehouse in Florence, Kentucky for retail medications.Source: VivioMD's terms of use page.

S4PASSThe footer of every page states that compounded drugs are not FDA-approved and do not undergo FDA review, and the product page states that compounded drug products are not approved or evaluated by the FDA.Source: VivioMD's website.

S5FAILNo certificate of analysis or lot document is published on the home page, the product page, the terms or the refund policy.Source: VivioMD's website; VivioMD's terms of use page; VivioMD's refund policy.

S6PASSVivioMD Group LLC at 16192 Coastal Highway, Lewes, DE 19958, printed as the contact address in the terms.Source: VivioMD's terms of use page.

S7PASSCompounded semaglutide injection at $249 a month, a GLP-1+GIP injection at $339 a month, GLP-1 tablets at $279 a month and GLP-1+GIP tablets at $339 a month, printed on the product page. The home page prints no price.Source: VivioMD's website.

S8PASSFDA warning letter 728295, June 2026, names VivioMD Group LLC doing business as VivioMD and reviewed this website. It alleges that the compounded semaglutide and tirzepatide products pictured on the website identify VivioMD on the label, suggesting VivioMD is the compounder when it is not. No close-out letter appears in the index. No FDA action has halted the business, and the seller still trades.Source: FDA's website; FDA warning letter 728295.

Products shown on the seller's own pages at the recorded date: compounded semaglutide injection, GLP-1+GIP injection, GLP-1 tablets, GLP-1+GIP tablets.

Other sellers of the same products

Who sells semaglutide

Enforcement documents on file: 1 warning letter

FDA warning letter 728295, issued June 2026, to VivioMD Group LLC dba VivioMDPictured labels identify VivioMD on the compounded semaglutide and tirzepatide products, suggesting VivioMD is the compounder of those drugs when it is not, which misbrands the products.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit VivioMD

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.